What treasury share transaction did GSK (GSK) announce in this 6-K?

GSK announced it transferred 22,000,000 ordinary shares from treasury to the GlaxoSmithKline Employee Trust to satisfy awards under its employee share plans.

GSK transfers 22M treasury shares to employee trust for plans

Q: What price was paid for the GSK treasury shares transferred to the employee trust?

The trustee of the GlaxoSmithKline Employee Trust paid £17.995 per ordinary share, funded by a loan from GlaxoSmithKline Services Unlimited.

Q: How many GSK shares remain in treasury after the transfer?

After the transfer, GSK holds 234,819,844 ordinary shares in treasury.

Q: What is the total number of GSK voting rights following this transaction?

The total number of voting rights in GSK is 4,080,611,266 following the transfer.

Q: Why did GSK transfer treasury shares to the GlaxoSmithKline Employee Trust?

The 22,000,000 ordinary shares were transferred so they can be used to satisfy awards under GSK’s Deferred Annual Bonus Plan, Performance Share Plan and Share Value Plan.

GSK plc reported that on 18 November 2025 it transferred 22,000,000 ordinary shares held in treasury to the GlaxoSmithKline Employee Trust, a Jersey resident trust.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

GSK plc reported that on 18 November 2025 it transferred 22,000,000 ordinary shares held in treasury to the GlaxoSmithKline Employee Trust, a Jersey resident trust. These shares will be used to satisfy awards under the company’s Deferred Annual Bonus Plan, Performance Share Plan and Share Value Plan. The trustee paid £17.995 per share, funded by a loan from GlaxoSmithKline Services Unlimited.

After the transfer, GSK holds 234,819,844 ordinary shares in treasury and has 4,080,611,266 ordinary shares in issue, excluding treasury shares. The total number of voting rights is 4,080,611,266, and the percentage of voting rights attributable to treasury shares is 5.75%, which is relevant for shareholders’ disclosure calculations under UK rules.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What price was paid for the GSK treasury shares transferred to the employee trust?

The trustee of the GlaxoSmithKline Employee Trust paid £17.995 per ordinary share, funded by a loan from GlaxoSmithKline Services Unlimited.

How many GSK shares remain in treasury after the transfer?

After the transfer, GSK holds 234,819,844 ordinary shares in treasury.

What is the total number of GSK voting rights following this transaction?

The total number of voting rights in GSK is 4,080,611,266 following the transfer.

What percentage of GSK voting rights is attributable to treasury shares?

GSK stated that, in accordance with DTR 5.5.1R, the percentage of voting rights attributable to its treasury shares is 5.75%.

Why did GSK transfer treasury shares to the GlaxoSmithKline Employee Trust?

The 22,000,000 ordinary shares were transferred so they can be used to satisfy awards under GSK’s Deferred Annual Bonus Plan, Performance Share Plan and Share Value Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 11/19/2025 - 08:46 AM EST

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Issued: 19 November 2025, London UK

Transfer of Treasury Shares

On 18 November 2025, GSK plc (the "Company") transferred 22,000,000 ordinary shares of 31¼ pence each ("Ordinary Shares") that were held by the Company in treasury ("Treasury Shares") to the Company's Jersey resident trust, the GlaxoSmithKline Employee Trust (the "Jersey Trust"), such Ordinary Shares to be used to satisfy awards granted under the Company's Deferred Annual Bonus Plan, Performance Share Plan and Share Value Plan. The consideration received from the trustee of the Jersey Trust, of £17.995 per Ordinary Share, was funded by a loan from GlaxoSmithKline Services Unlimited.

Following the transfer, the Company will hold 234,819,844 Ordinary Shares in treasury and have 4,080,611,266 Ordinary Shares in issue (excluding Treasury Shares).

The total number of voting rights in the Company is 4,080,611,266. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The Company confirms that, in accordance with DTR 5.5.1R, following the above transfer the percentage of voting rights attributable to the Treasury Shares is 5.75%.

This announcement is made in accordance with the requirements of UK Listing Rule 9.8.2.

Notifications may be sent to company.secretary@gsk.com.

V A Whyte

Company Secretary

19 November 2025

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

	GSK plc
	(Registrant)

Date: November 19, 2025

	By:/s/ VICTORIA WHYTE --------------------------

	Victoria Whyte
	Authorised Signatory for and on
	behalf of GSK plc

Source: View Original Filing on SEC EDGAR